What compounding means
Compounding is the process of preparing a medication specifically for an individual patient when commercially available products do not meet that patient's needs. In the context of peptide therapy, compounding is used when:
- An FDA-approved drug exists but is in shortage (as happened with semaglutide and tirzepatide)
- A patient needs a specific dose or formulation not available in commercial products
- A peptide with legitimate prescribing uses has no commercially manufactured version (common for peptides like sermorelin, tesamorelin, or PT-141 at certain doses)
Compounding pharmacies in the US operate under a specific legal framework established by the Drug Quality and Security Act (DQSA) of 2013, which created two categories of compounders.
503A vs 503B pharmacies: the key difference
503A pharmacies (traditional compounding pharmacies):
- Prepare medications for individual patients based on a valid prescription from a licensed prescriber
- Are regulated primarily by state pharmacy boards
- Do not need to register with the FDA
- Are subject to state Good Manufacturing Practice (GMP) standards, which vary by state
- Can only prepare medications in quantities appropriate for individual patient prescriptions - not for bulk sale or distribution to clinics
503B pharmacies (outsourcing facilities):
- Register with the FDA and are subject to federal Current Good Manufacturing Practice (CGMP) standards - the same standards applied to pharmaceutical manufacturers
- Can produce larger batches of medications without individual patient prescriptions
- Are subject to FDA inspection
- Provide a higher level of quality assurance than 503A compounders for sterile preparations
For injectable peptides, 503B pharmacies are generally considered the higher-quality option because of the stricter standards for sterile manufacturing. Many reputable telehealth clinics work specifically with 503B pharmacies for this reason.
The FDA's position on compounded peptides
The FDA's stance on compounded medications is nuanced. The agency does not approve compounded drugs, but it does regulate the pharmacies that produce them - particularly 503B facilities.
Key FDA positions relevant to compounded peptides:
During drug shortages: The FDA has permitted compounding of medications like semaglutide and tirzepatide when those drugs appear on the FDA Drug Shortage list, even though they are otherwise protected by patents. When shortage designations are removed, this permission changes.
Novel drug compounds: The FDA does not permit compounding of drugs that are essentially copies of commercially available approved drugs (outside shortage exceptions). However, many peptides used in longevity and performance medicine do not have commercially available versions, which gives compounding pharmacies more latitude.
Research use only products: Products labeled as "research use only" or "not for human use" are not legally sold for administration to humans. Any clinic using such products to treat patients is operating outside the law, regardless of what their website says.
Quality concerns: The FDA has issued warning letters to compounding pharmacies for contamination, inaccurate dosing, and poor sterile technique. These risks are real and are part of why the pharmacy your clinic uses matters.
How to verify a compounding pharmacy
Before starting any compounded peptide program, ask your clinic which pharmacy produces the medication. Then verify the pharmacy independently.
For 503B pharmacies:
- The FDA maintains a public list of registered 503B outsourcing facilities on its website (fda.gov)
- Search for the pharmacy name to confirm it is registered and check for any recent warning letters or enforcement actions
For 503A pharmacies:
- Check your state pharmacy board's license verification database
- Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation, which is voluntary but indicates a higher standard of practice
- Ask the clinic whether the pharmacy has had any FDA inspections and what the outcomes were
Questions to ask any compounding pharmacy:
- Are you a 503A or 503B facility?
- Can you provide a Certificate of Analysis (CoA) for the batch used in my prescription? (This confirms potency and purity testing)
- What sterile manufacturing standards do you follow for injectables?
- How is the medication shipped and stored?
Why the pharmacy matters more than you might think
Injectable compounded peptides carry inherent risks if produced incorrectly. The most significant risks from poor compounding practice include:
- Contamination - bacterial or fungal contamination in injectable medications can cause serious infections
- Inaccurate potency - medication that is significantly over- or under-dosed can cause harm or simply not work
- Incorrect salt forms - some compounding pharmacies have used incorrect chemical forms of peptides (such as semaglutide acetate vs semaglutide free acid base), which may affect how the medication is absorbed and distributed
These are not theoretical concerns. The FDA has documented cases of compounding pharmacy failures across all of these categories. Choosing a clinic that uses a reputable, verifiable 503B pharmacy is one of the most concrete ways to reduce your risk.
Patient rights and responsibilities
When receiving compounded medications through a US physician-supervised program, you have the right to:
- Know the name and location of the compounding pharmacy
- Request a Certificate of Analysis for your medication
- Ask your physician about the clinical rationale for the specific compound and dose
- Stop treatment at any time and request your medical records
Your responsibilities include:
- Providing accurate health history and medication lists
- Attending scheduled follow-up consultations
- Reporting side effects or concerns promptly
- Storing medications as instructed (most injectables require refrigeration)
Find physician-supervised peptide clinics that work with verified compounding pharmacies and can answer your questions about their pharmacy partners.